AndrioBioSys at the Buffalo Niagara Medical Campus
AndroBioSys provides proprietary contract research services in the angiogenesis area and has established models that use isolated cancerous human prostate, breast and ovarian cells and tissues.
The goal of the company is to develop targeted therapeutics and provide preclinical testing assays that will be more predictive of clinical efficacy. The high cost of drug development requires better, more predictive models for testing therapeutics to reduce the failure rate at the expensive later stages of clinical trials, as the cost to develop a drug that will reach the market currently is predicted to exceed $1.7 billion.
With record numbers of drugs coming off patent and the shifting demographics of an aging population, AndroBioSys is poised to assist in filling the diminishing drug pipeline.
The company is located on the Buffalo Niagara Medical Campus adjacent to the Roswell Park Cancer Institute, Hauptman Woodward Institute and the New York State Center of Excellence.